Traitement antithrombotique et cancer

详细信息    查看全文

• 作者：Guy Meyer ; Olivier Sanchez ; Benjamin Planquette
• 刊名：La Presse M|dicale
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：42
• 期：9_part_P1
• 页码：1239-1245
• 全文大小：227 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Key points

Five to 10? % of cancers are complicated by venous thromboembolism.

A score is available to classify patients according to their risk of venous thromboembolism.

The long-term prophylaxis is not recommended in patients with cancer, even if it reduces the incidence of thromboembolic events, due to the high number of patients to treat to prevent one event.

The treatment of venous thromboembolism in cancer is based on the use of low-molecular weight heparin for at least 3 months.

The potential role of antithrombotic drugs in the prevention and adjuvant treatment of some cancers is being evaluated.